Clinical Trials at MPTC

 
The Maryland Proton Treatment Center (MPTC) is dedicated to advancing scientific knowledge about the role of proton therapy in the treatment of cancer. All patients treated at MPTC have access to a wide range of clinical trials. The center currently has trials open for:
 

All Cancer Sites

  • MPTC Bio Repository [Sponsor: U. Maryland]
  • NCT01255748: Evaluation Tracking Project: A Prospective Chart Review of Patients Treated with Radiation Therapy [Sponsor: Proton Collaborative Group (PCG)]
     

Breast

  • NCT02603341: Pragmatic Phase III Randomized Trial of Photon vs Proton Therapy for Patients with Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial [Sponsor: U. Pennsylvania]
  • NCT01766297: Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer [Sponsor: PCG]

Central Nervous System

  • NCT02179086: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma [Sponsor: NRG]
  • NCT01925573: Proposed Pilot Study of Combined Optune+ Bevacizumab, and Hypofractionated Stereotactic Irradiation for Bevacizumab-Native Recurrent Glioblastoma [Sponsor: U.Maryland]
  • NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) (150kHz) for 1-10 Brain Metastases From Non-Small Cell Lung Cancer (NSCLC) [Sponsor: NovoCure]
  • NCT03180268: Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma [Sponsor: NRG]
     

Head and Neck

  • NCT01893307: Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck [Sponsor: M.D. Anderson]
  • NCT02289209: A Phase II Trial of Re-Irradiation Combined with Open Label MK-3475 (Pembrolizumab) in Patients with Loco-Regional Inoperable Recurrence or Second Primary Squamous Cell Carcinoma of the Head and Neck (SCCHN) [Sponsor: U. Maryland]
  • NCT03480971: A Double Blind, Placebo Controlled Dose Range Finding Study to Assess the Safety, Pharmacokinetics, and Efficacy of Tempol for the Reduction of Severe Mucositis in Head and Neck Cancer Patients Undergoing Combined Radio- and Chemotherapy [Sponsor: Matrix Biomed, Inc.]
     

Gastrointestinal

  • NCT03186898: A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma [Sponsor: NRG]
  • NCT03652428: Phase I Study of Concurrent Nab-Paclitaxel + Gemcitabine With Hypofractionated, Ablative Proton Therapy for Locally Advanced Pancreatic Cancer [Sponsor: U.Maryland]

Lung

  • NCT01770418: A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer [Sponsor: PCG]
  • NCT01993810: Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC [Sponsor: RTOG]
  • NCT02567799: A Phase I/II Clinical Study Evaluating the Safety and Effectiveness of BIO 300 Oral Suspension in Patients Receiving Chemoradiation Therapy for Non-Small Cell Lung Cancer (NSCLC) [Sponsor: Humanetics Corporation]
     

Pediatric

  • NCT01696721: Pediatric Proton Consortium Registry (PPCR): A Multi-Center Registry of Pediatric Patients Treated with Proton Radiation Therapy [Sponsor: MGH]
     

Prostate

  • NCT01230866: A Phase III Prospective Randomized Trial of Standard-fractionation vs Hypofractionation with Proton Radiation Therapy for Low Risk Adenocarcinoma of the Prostate [Sponsor: PCG]
  • NCT01617161: Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): A Phase III Randomized Clinical Trial of Proton Therapy Versus IMRT for Low or Intermediate Risk Prostate Cancer [Sponsor: MGH]
  • NCT03194516: A Ketogenic Diet Pilot Study of Overweight Prostate Cancer Patients on Active Surveillance [Sponsor: U Maryland]
For further information on MPTC clinical trials, please call (410) 328-2635.

Request a Consult

I am a